Annotation Detail

Information
Associated Genes
BRAF
Associated Variants
BRAF V600
BRAF V600
Associated Disease
colorectal cancer
Source Database
CIViC Evidence
Description
Patients with BRAF-V600 mutated cancers were identified (n=122) and subsequently underwent targeted therapy. 27 patients with colorectal cancer were treated with vemurafenib and cetuximab (N=24 with BRAF V600E mutation, N=3 with V600 unknown status). One response was observed; however, approximately half the patients had tumor regression that did not meet the standard criteria for a partial response. Median progression-free survival and overall survival for patients receiving combination therapy were 3.7 months (95% CI, 1.8 to 5.1) and 7.1 months (95% CI, 4.4 to not reached), respectively. Patients were heavily pretreated, with a median of two lines of previous therapy (range, one to six).
Evidence Type
Predictive
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1598
Gene URL
https://civic.genome.wustl.edu/links/genes/5
Variant URL
https://civic.genome.wustl.edu/links/variants/17
Rating
2
Disease
Colorectal Cancer
Evidence Direction
Does Not Support
Drug
Cetuximab,Vemurafenib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
26287849
Drugs
Drug NameSensitivitySupported
CetuximabSensitivityfalse
VemurafenibSensitivityfalse